Exhibit 99.3
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
Following are some of the key points regarding PDL’s first quarter 2016 financial and business results.
Highlighted Financial Results from Q1 2016
| |
| • | Total revenues of $103.1 million for the first quarter of 2016. |
| |
| • | Non-GAAP diluted earnings per share (EPS) of $0.52 increased approximately 11 percent versus the same period in 2015. |
| |
| • | Non-GAAP net income increased 7 percent to $84.8 million. |
| |
| • | GAAP diluted EPS of $0.34, decreased by 32 percent compared to the same period of 2015. |
| |
| • | GAAP net income decreased by 34 percent to $55.9 million. |
The largest component of the difference in non-GAAP measure compared to GAAP is the exclusion of mark-to-market
adjustments related to the fair value election of our investments in royalty rights. A full reconciliation of all components of the GAAP to Non-GAAP quarterly financial results can be found in Table 4 at the end of the PDL press release dated May 4, 2016.
Updates on Approved Royalty Bearing Products related to Queen et al. patents
Under the terms of the legal settlement between Genentech and PDL, the first quarter of 2016 is the last period for which Genentech will pay royalties to PDL for Avastin®, Herceptin®, Xolair®, Kadcyla® and Perjeta®. Royalty payments for Avastin®, Herceptin®, Xolair®, Kadcyla® and Perjeta® accounted for 86% of the $121.5 million Queen et al. royalty revenue recognized in the first quarter of 2016. Other products from the Queen et al. patent licenses entitle us to royalties following the expiration of our patents with respect to sales of licensed product manufactured prior to patent expiry in jurisdictions providing patent protection licenses. The amount of royalties we are due for product manufactured prior to patent expiry but sold after patent expiry is uncertain, however, the Company's revenues from payments made from these Queen et al. patent licenses and settlements will materially decrease in the second quarter of 2016.
Avastin® (bevacizumab):
| |
| • | On April 19, 2016, Genentech/Roche reported that Q116 sales were CHF 1.706 billion. |
Herceptin® (trastuzumab):
| |
| • | On April 19, 2016, Genentech/Roche reported that Q116 sales were CHF 1.725 billion. |
Xolair® (omalizumab):
| |
| • | On April 19, 2016, Genentech/Roche reported that Q116 sales were CHF 356 million. |
Tysabri® (natalizumab):
| |
| • | On April 21, 2016, Biogen reported that Q116 sales were $477 million. |
Perjeta® (pertuzumab):
| |
| • | On April 19, 2016, Genentech/Roche reported that Q116 sales were CHF 439 million. |
Kadcyla® (TDM-1 or ado-trastuzumab emtansine):
| |
| • | On April 19, 2016, Genentech/Roche reported that Q116 sales were CHF 201 million. |
Updates on Unapproved Royalty Bearing Products Related to Queen et al. patents
Solanezumab
| |
| • | On January 5, 2016, Lilly re-affirmed that topline data from its Phase 3 trial in patients with mild Alzheimer’s Disease is expected in late 2016. |
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
| |
| • | Lilly announced that it is moving from a co-primary endpoint of cognitive and functional change to a single endpoint of cognitive change with functional change as a secondary endpoint. |
Updates on Income Generating Assets
Wellstat Diagnostics, LLC
| |
| • | PDL has moved for summary judgment in New York state court to enforce guarantees related to non-Wellstat Diagnostics’ assets. |
| |
| • | A hearing was scheduled in the Maryland Circuit Court for April 13, 2016 to hear the Receiver’s motion to approve the credit bid sale to PDL. However, on April 12, 2016, Wellstat Diagnostics changed its name to Defined Diagnostics, LLC and filed for bankruptcy under Chapter 11 in the United States Bankruptcy Court in the Southern District of New York. The filing of the bankruptcy case stays the proceedings in the Maryland Circuit Court pursuant to the automatic stay provisions of the Bankruptcy Code. |
| |
| • | Because the bankruptcy filing is a transparent attempt to delay the receiver sale to PDL, we intend to file a petition with the bankruptcy court to dismiss the bankruptcy filing with prejudice and allow the case to continue in the receiver court. |
Depomed, Inc.
| |
| • | We have reduced the fair market value of the Depomed royalty rights by $47.9 million, primarily due to a reduction in Glumetza royalties received and a reduction in future cash flows due to lower projected demand data, greater erosion of market share due to the launch of a generic, and higher gross-to-net adjustments for Glumetza. As you will recall, Glumetza was marketed by Salix until its acquisition by Valeant. Because we have limited information from Valeant, we employ an independent third party consulting group to assist us in our quarterly evaluation of Glumetza and the other Depomed products on which we receive or will receive royalties. In February 2016, a generic competitor to Glumetza launched as expected. The impact of the generic has been greater than typical generic erosion models would predict resulting in less demand for Glumetza. |
| |
| • | PDL and Depomed are in the process of conducting a royalty audit on Glumetza royalties owed by Valeant. |
Direct Flow Medical, Inc.
| |
| • | Hired Daniel Lemaitre as CEO, former CEO of CoreValve, one of the early pioneers in transcatheter aortic valves, which was sold to Medtronic. |
| |
| • | Hired David Boyle as CFO, formerly CFO of AVI BioPharma, Bionovo and Salix. |
| |
| • | In January 2016, PDL funded additional $5 million secured loan convertible into equity at our option; with an additional $5 million secured convertible loan tranche to be funded at PDL’s option. |
kaleo, Inc.
| |
| • | On February 18, 2016, PDL was advised that Sanofi and kaléo will terminate their license and development agreement later this year. |
| |
| • | On March 31, 2016, PDL was informed by kaléo that the license and development agreement was terminated and that all U.S. and Canadian commercial and manufacturing rights to Auvi-Q® and Allerject® had been returned to kaléo. All manufacturing equipment had also been returned to kaléo, and they intend to evaluate the timing and options for bringing Auvi-Q and Allerject® back to the market. |
| |
| • | PDL entered into a secured note purchase agreement with Accel 300, a wholly-owned subsidiary of kaléo, which as of December 31, 2015, had a principal balance of $144.8 million due to PDL. An interest reserve account previously set up as part of the note agreement will substantially cover interest payments due to PDL through the end of the second quarter of 2016, and kaléo has indicated that it intends to make payments due to PDL under the note agreement until Auvi-Q is returned to the market. |
Forward-looking Statements
This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K, as updated by subsequent quarterly reports filed with the Securities and Exchange Commission, as updated by subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward looking statement except as required by law.
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
|
| | | | | | | | | | |
| Queen et al. Royalties |
| Royalty Revenue by Product ($ in 000's) * |
| Avastin | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 38,825 |
| — |
| — |
| — |
| 38,825 |
|
| 2015 | 38,809 |
| 38,447 |
| 39,284 |
| 39,987 |
| 156,527 |
|
| 2014 | 38,122 |
| 38,924 |
| 38,864 |
| 40,723 |
| 156,632 |
|
| 2013 | 33,234 |
| 46,720 |
| 32,224 |
| 32,287 |
| 144,464 |
|
| 2012 | 23,215 |
| 41,670 |
| 25,955 |
| 30,041 |
| 120,882 |
|
| 2011 | 22,283 |
| 41,967 |
| 23,870 |
| 22,886 |
| 111,006 |
|
| 2010 | 16,870 |
| 44,765 |
| 29,989 |
| 24,922 |
| 116,547 |
|
| 2009 | 13,605 |
| 35,161 |
| 21,060 |
| 15,141 |
| 84,966 |
|
| 2008 | 9,957 |
| 30,480 |
| 19,574 |
| 12,394 |
| 72,405 |
|
| 2007 | 8,990 |
| 21,842 |
| 17,478 |
| 9,549 |
| 57,859 |
|
| 2006 | 10,438 |
| 15,572 |
| 15,405 |
| 12,536 |
| 53,952 |
|
| Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 38,726 |
| — |
| — |
| — |
| 38,726 |
|
| 2015 | 37,875 |
| 39,476 |
| 39,457 |
| 38,897 |
| 155,704 |
|
| 2014 | 36,646 |
| 38,292 |
| 39,407 |
| 40,049 |
| 154,394 |
|
| 2013 | 30,287 |
| 47,353 |
| 30,961 |
| 33,038 |
| 141,640 |
|
| 2012 | 25,702 |
| 44,628 |
| 30,433 |
| 28,307 |
| 129,070 |
|
| 2011 | 25,089 |
| 42,209 |
| 31,933 |
| 21,812 |
| 121,042 |
|
| 2010 | 23,402 |
| 38,555 |
| 27,952 |
| 25,441 |
| 115,350 |
|
| 2009 | 16,003 |
| 32,331 |
| 26,830 |
| 18,615 |
| 93,779 |
|
| 2008 | 14,092 |
| 34,383 |
| 28,122 |
| 20,282 |
| 96,880 |
|
| 2007 | 19,035 |
| 28,188 |
| 22,582 |
| 14,802 |
| 84,608 |
|
| 2006 | 15,142 |
| 19,716 |
| 21,557 |
| 20,354 |
| 76,769 |
|
| Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 15,920 |
| — |
| — |
| — |
| 15,920 |
|
| 2014 | 17,390 |
| 16,777 |
| 16,883 |
| 16,695 |
| 67,746 |
|
| 2013 | 12,032 |
| 30,066 |
| 13,536 |
| 12,127 |
| 67,760 |
|
| 2012 | 10,791 |
| 27,938 |
| 12,552 |
| 11,097 |
| 62,377 |
|
| 2011 | 8,878 |
| 24,313 |
| 12,157 |
| 10,750 |
| 56,099 |
|
| 2010 | 7,220 |
| 19,091 |
| 10,841 |
| 8,047 |
| 45,198 |
|
| 2009 | 4,621 |
| 12,863 |
| 8,123 |
| 6,152 |
| 31,759 |
|
| 2008 | 3,636 |
| 11,060 |
| 7,631 |
| 4,549 |
| 26,876 |
|
| 2007 | 2,931 |
| 6,543 |
| 6,579 |
| 3,517 |
| 19,570 |
|
| 2006 | — |
| — |
| 289 |
| 3,335 |
| 3,624 |
|
| Xolair | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 13,030 |
| — |
| — |
| — |
| 13,030 |
|
| 2015 | 10,971 |
| 11,075 |
| 12,407 |
| 12,749 |
| 47,202 |
|
| 2014 | 8,886 |
| 9,099 |
| 10,442 |
| 11,237 |
| 39,663 |
|
| 2013 | 5,930 |
| 10,025 |
| 7,334 |
| 7,330 |
| 30,619 |
|
| 2012 | 5,447 |
| 8,609 |
| 6,504 |
| 6,145 |
| 26,705 |
|
| 2011 | 4,590 |
| 7,621 |
| 5,916 |
| 5,823 |
| 23,949 |
|
| 2010 | 3,723 |
| 6,386 |
| 4,980 |
| 4,652 |
| 19,741 |
|
| 2009 | 2,665 |
| 5,082 |
| 4,085 |
| 3,722 |
| 15,553 |
|
| 2008 | 1,488 |
| 4,866 |
| 3,569 |
| 2,927 |
| 12,850 |
|
| 2007 | 1,684 |
| 3,942 |
| 3,332 |
| 2,184 |
| 11,142 |
|
| 2006 | 2,263 |
| 2,969 |
| 3,041 |
| 2,495 |
| 10,768 |
|
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
|
| | | | | | | | | | |
| Queen et al. Royalties |
| Royalty Revenue by Product ($ in 000's) * |
| Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 9,320 |
| — |
| — |
| — |
| 9,320 |
|
| 2015 | 6,596 |
| 7,419 |
| 7,898 |
| 8,753 |
| 30,666 |
|
| 2014 | 3,375 |
| 4,385 |
| 5,157 |
| 5,850 |
| 18,767 |
|
| 2013 | 340 |
| 1,414 |
| 748 |
| 879 |
| 3,381 |
|
| 2012 | — |
| — |
| 58 |
| 250 |
| 308 |
|
| Kadcyla | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 4,782 |
| — |
| — |
| — |
| 4,782 |
|
| 2015 | 3,852 |
| 4,177 |
| 4,319 |
| 4,535 |
| 16,883 |
|
| 2014 | 1,934 |
| 2,491 |
| 3,048 |
| 3,464 |
| 10,937 |
|
| 2013 | — |
| 551 |
| 830 |
| 859 |
| 2,240 |
|
| Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 13,970 |
| — |
| — |
| — |
| 13,970 |
|
| 2015 | 14,385 |
| 13,614 |
| 13,557 |
| 14,031 |
| 55,587 |
|
| 2014 | 12,857 |
| 13,350 |
| 16,048 |
| 15,015 |
| 57,270 |
|
| 2013 | 12,965 |
| 13,616 |
| 11,622 |
| 12,100 |
| 50,304 |
|
| 2012 | 11,233 |
| 12,202 |
| 11,749 |
| 12,255 |
| 47,439 |
|
| 2011 | 9,891 |
| 10,796 |
| 11,588 |
| 11,450 |
| 43,725 |
|
| 2010 | 8,791 |
| 8,788 |
| 8,735 |
| 9,440 |
| 35,754 |
|
| 2009 | 6,656 |
| 7,050 |
| 7,642 |
| 8,564 |
| 29,912 |
|
| 2008 | 3,883 |
| 5,042 |
| 5,949 |
| 6,992 |
| 21,866 |
|
| 2007 | 839 |
| 1,611 |
| 2,084 |
| 2,836 |
| 7,370 |
|
| 2006 | — |
| — |
| — |
| 237 |
| 237 |
|
| Actemra | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 4,990 |
| — |
| — |
| — |
| 4,990 |
|
| 2014 | 3,446 |
| 3,932 |
| 4,419 |
| 5,406 |
| 17,202 |
|
| 2013 | 2,631 |
| 2,816 |
| 2,939 |
| 3,744 |
| 12,131 |
|
| 2012 | 1,705 |
| 2,074 |
| 2,145 |
| 2,462 |
| 8,385 |
|
| 2011 | 913 |
| 1,136 |
| 1,401 |
| 1,460 |
| 4,910 |
|
| 2010 | 1,587 |
| 237 |
| 315 |
| 688 |
| 2,827 |
|
| 2009 | 585 |
| 537 |
| 909 |
| 1,197 |
| 3,228 |
|
| 2008 | 44 |
| — |
| 146 |
| 369 |
| 559 |
|
| 2007 | 32 |
| — |
| — |
| 17 |
| 49 |
|
| Gazyva | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 313 |
| — |
| — |
| — |
| 313 |
|
| 2014 | 51 |
| 283 |
| 325 |
| 436 |
| 1,094 |
|
| Entyvio | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 2,223 |
| — |
| — |
| — |
| 2,223 |
|
| 2014 | — |
| — |
| 153 |
| 2,192 |
| 2,344 |
|
| * As reported to PDL by its licensees. Totals may not sum due to rounding. |
| Q1 2014 royalty revenue by product above do not include a $5 million payment received from Genentech in Q1 2014 for a retroactive settlement payment from 2013. |
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
|
| | | | | | | | | | |
| Queen et al. Sales Revenue |
| Reported Licensee Net Sales Revenue by Product ($ in 000's) * |
| Avastin | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 1,827,081 |
| — |
| — |
| — |
| 1,827,081 |
|
| 2015 | 1,826,289 |
| 1,809,286 |
| 1,848,655 |
| 1,881,743 |
| 7,365,972 |
|
| 2014 | 1,786,912 |
| 1,838,764 |
| 1,828,900 |
| 1,916,353 |
| 7,370,929 |
|
| 2013 | 1,653,108 |
| 1,694,678 |
| 1,746,135 |
| 1,819,877 |
| 6,913,798 |
|
| 2012 | 1,502,757 |
| 1,573,727 |
| 1,551,327 |
| 1,662,977 |
| 6,290,788 |
|
| 2011 | 1,597,461 |
| 1,582,705 |
| 1,581,095 |
| 1,469,994 |
| 6,231,255 |
|
| 2010 | 1,506,788 |
| 1,596,892 |
| 1,594,707 |
| 1,646,218 |
| 6,344,605 |
|
| 2009 | 1,345,487 |
| 1,295,536 |
| 1,439,730 |
| 1,514,053 |
| 5,594,806 |
|
| 2008 | 980,715 |
| 1,084,930 |
| 1,180,427 |
| 1,239,382 |
| 4,485,454 |
|
| 2007 | 678,068 |
| 746,587 |
| 797,013 |
| 875,084 |
| 3,096,752 |
|
| 2006 | 439,318 |
| 516,052 |
| 570,551 |
| 592,897 |
| 2,118,817 |
|
| Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 1,822,407 |
| — |
| — |
| — |
| 1,822,407 |
|
| 2015 | 1,789,404 |
| 1,857,696 |
| 1,856,803 |
| 1,830,424 |
| 7,334,326 |
|
| 2014 | 1,731,564 |
| 1,801,990 |
| 1,854,452 |
| 1,877,614 |
| 7,265,621 |
|
| 2013 | 1,681,574 |
| 1,744,145 |
| 1,681,860 |
| 1,726,551 |
| 6,834,130 |
|
| 2012 | 1,515,255 |
| 1,625,313 |
| 1,663,695 |
| 1,650,495 |
| 6,454,759 |
|
| 2011 | 1,391,568 |
| 1,559,975 |
| 1,642,898 |
| 1,432,771 |
| 6,027,211 |
|
| 2010 | 1,270,846 |
| 1,349,512 |
| 1,300,934 |
| 1,409,310 |
| 5,330,602 |
|
| 2009 | 1,210,268 |
| 1,133,993 |
| 1,226,435 |
| 1,278,626 |
| 4,849,323 |
|
| 2008 | 1,105,426 |
| 1,195,215 |
| 1,211,982 |
| 1,186,806 |
| 4,699,428 |
|
| 2007 | 891,761 |
| 949,556 |
| 979,602 |
| 1,015,033 |
| 3,835,952 |
|
| 2006 | 529,585 |
| 659,719 |
| 761,099 |
| 803,576 |
| 2,753,979 |
|
| Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 749,182 |
| — |
| — |
| — |
| 749,182 |
|
| 2014 | 818,376 |
| 789,483 |
| 794,505 |
| 785,669 |
| 3,188,031 |
|
| 2013 | 1,203,179 |
| 1,171,423 |
| 1,200,791 |
| 1,212,651 |
| 4,788,045 |
|
| 2012 | 1,079,092 |
| 1,086,543 |
| 1,097,541 |
| 1,109,695 |
| 4,372,871 |
|
| 2011 | 887,757 |
| 943,418 |
| 1,052,809 |
| 1,075,015 |
| 3,958,999 |
|
| 2010 | 721,967 |
| 698,890 |
| 745,376 |
| 804,684 |
| 2,970,917 |
|
| 2009 | 462,103 |
| 469,736 |
| 555,296 |
| 615,212 |
| 2,102,347 |
|
| 2008 | 363,615 |
| 393,682 |
| 460,167 |
| 454,922 |
| 1,672,386 |
|
| 2007 | 224,820 |
| 219,579 |
| 299,995 |
| 322,300 |
| 1,066,695 |
|
| 2006 | — |
| — |
| 10,689 |
| 157,742 |
| 168,431 |
|
| Xolair | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 613,160 |
| — |
| — |
| — |
| 613,160 |
|
| 2015 | 523,340 |
| 521,192 |
| 583,856 |
| 599,945 |
| 2,228,333 |
|
| 2014 | 425,243 |
| 428,171 |
| 491,372 |
| 521,726 |
| 1,866,512 |
|
| 2013 | 341,309 |
| 365,778 |
| 391,900 |
| 401,333 |
| 1,500,321 |
|
| 2012 | 310,234 |
| 314,638 |
| 347,796 |
| 340,431 |
| 1,313,100 |
|
| 2011 | 267,754 |
| 277,642 |
| 310,874 |
| 314,911 |
| 1,171,182 |
|
| 2010 | 228,859 |
| 225,878 |
| 251,055 |
| 263,389 |
| 969,179 |
|
| 2009 | 184,669 |
| 181,086 |
| 211,006 |
| 219,693 |
| 796,454 |
|
| 2008 | 137,875 |
| 169,521 |
| 177,179 |
| 183,753 |
| 668,329 |
|
| 2007 | 129,172 |
| 130,700 |
| 144,250 |
| 147,754 |
| 551,876 |
|
| 2006 | 95,241 |
| 99,354 |
| 112,608 |
| 118,002 |
| 425,204 |
|
PDL BioPharma, Inc.
Q1 2016
May 4, 2016
|
| | | | | | | | | | |
| Queen et al. Sales Revenue |
| Reported Licensee Net Sales Revenue by Product ($ in 000's) * |
| Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 438,580 |
| — |
| — |
| — |
| 438,580 |
|
| 2015 | 310,410 |
| 349,125 |
| 371,668 |
| 411,912 |
| 1,443,115 |
|
| 2014 | 158,809 |
| 206,333 |
| 242,700 |
| 275,311 |
| 883,153 |
|
| 2013 | 34,008 |
| 55,076 |
| 66,353 |
| 87,949 |
| 243,386 |
|
| 2012 | — |
| — |
| 5,080 |
| 25,000 |
| 30,079 |
|
| Kadcyla | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 25,018 |
| — |
| — |
| — |
| 25,018 |
|
| 2015 | 181,275 |
| 196,556 |
| 203,258 |
| 213,404 |
| 794,493 |
|
| 2014 | 91,031 |
| 117,212 |
| 143,414 |
| 163,028 |
| 514,685 |
|
| 2013 | — |
| 21,459 |
| 73,626 |
| 85,906 |
| 180,991 |
|
| Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | 465,647 |
| — |
| — |
| — |
| 465,647 |
|
| 2015 | 479,526 |
| 453,786 |
| 451,898 |
| 467,735 |
| 1,852,945 |
|
| 2014 | 428,561 |
| 442,492 |
| 534,946 |
| 500,511 |
| 1,906,510 |
|
| 2013 | 434,677 |
| 451,358 |
| 387,407 |
| 403,334 |
| 1,676,776 |
|
| 2012 | 374,430 |
| 401,743 |
| 391,623 |
| 408,711 |
| 1,576,508 |
|
| 2011 | 329,696 |
| 356,876 |
| 388,758 |
| 381,618 |
| 1,456,948 |
|
| 2010 | 293,047 |
| 287,925 |
| 293,664 |
| 316,657 |
| 1,191,292 |
|
| 2009 | 221,854 |
| 229,993 |
| 257,240 |
| 285,481 |
| 994,569 |
|
| 2008 | 129,430 |
| 163,076 |
| 200,783 |
| 233,070 |
| 726,359 |
|
| 2007 | 30,468 |
| 48,715 |
| 71,972 |
| 94,521 |
| 245,675 |
|
| 2006 | — |
| — |
| — |
| 7,890 |
| 7,890 |
|
| Actemra | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 166,338 |
| — |
| — |
| — |
| 166,338 |
|
| 2014 | 114,865 |
| 124,736 |
| 147,285 |
| 180,197 |
| 567,082 |
|
| 2013 | 87,703 |
| 91,374 |
| 97,961 |
| 124,815 |
| 401,852 |
|
| 2012 | 56,662 |
| 66,624 |
| 71,505 |
| 82,053 |
| 276,843 |
|
| 2011 | 30,433 |
| 35,370 |
| 46,709 |
| 48,671 |
| 161,183 |
|
| 2010 | 52,908 |
| 5,405 |
| 10,493 |
| 22,919 |
| 91,725 |
|
| 2009 | 19,504 |
| 17,920 |
| 30,313 |
| 39,888 |
| 107,625 |
|
| 2008 | 1,452 |
| 1,377 |
| 5,981 |
| 12,305 |
| 21,115 |
|
| 2007 | — |
| — |
| — |
| 1,137 |
| 1,137 |
|
| Gazyva | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 9,627 |
| — |
| — |
| — |
| 9,627 |
|
| 2014 | 3,095 |
| 8,697 |
| 11,531 |
| 13,428 |
| 36,750 |
|
| Entyvio | Q1 | Q2 | Q3 | Q4 | Total |
| 2016 | — |
| — |
| — |
| — |
| — |
|
| 2015 | 59,287 |
| — |
| — |
| — |
| 59,287 |
|
| 2014 | — |
| — |
| 5,347 |
| 58,500 |
| 63,848 |
|
| * As reported to PDL by its licensee. Dates in above charts reflect when PDL receives |
| royalties on sales. Sales occurred in the quarter prior to the dates in the above charts. |
| Totals may not sum due to rounding. | |
